StockData

Drugs Made In America Acquisition II Corp. (DMII) stock

DMIINasdaqBlank ChecksFiscal year ends December 31Also trades as DMIIR, DMIIU
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$10.23−0.01 (-0.15%)

Close on Nov 18, 2026Market cap $140.15MP/E –Yield –

Drugs Made In America Acquisition II operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Drugs Made In America Acquisition II's operating cash flow for the twelve months ending Sep 30, 2026 was -$646.86K. For fiscal 2025 it was -$1.02M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.02M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$56.74K–
Q2 FY2026Jun 30, 2026-$172.75K–
Q1 FY2026Mar 31, 2026-$102.50K–
Q4 FY2025Dec 31, 2025-$314.86K–
Q3 FY2025Sep 30, 2025-$690.73K–
Q2 FY2025Jun 30, 2025-$2.60K–
Q1 FY2025Mar 31, 2025-$10.04K–

More Drugs Made In America Acquisition II figures

See a number that looks wrong?